Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jul;89(4):F300-4.
doi: 10.1136/adc.2003.033555.

A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome

Affiliations
Clinical Trial

A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome

L Jackson et al. Arch Dis Child Fetal Neonatal Ed. 2004 Jul.

Abstract

Background: The incidence of neonatal abstinence syndrome (NAS) has increased 10-fold over the last decade in Glasgow. In the Princess Royal Maternity Hospital, it now accounts for 17% of special care baby unit (SCBU) admissions.

Objective: To compare opiate replacement therapy (morphine sulphate) with the present standard treatment (phenobarbitone) for management of NAS. The primary study end point was duration of pharmaceutical treatment. Secondary end points were the requirement for additional drugs and the requirement for SCBU admission.

Design: Double blind, randomised controlled clinical trial.

Methods: Differential diagnoses were excluded, and two consecutive Lipsitz scores > 4 defined NAS requiring treatment. Infants were randomised to receive morphine sulphate or phenobarbitone. Treatments were identical in appearance, odour, and volume. Increments, decrements, and discontinuation of treatments were protocol driven.

Results: Seventy five infants participated. All mothers received opiate replacement therapy (methadone) during pregnancy and most used other drugs (n = 62, 83%). No significant difference in maternal drug use patterns was observed between treatment groups. Median treatment duration was four days shorter with opiate replacement (8 v 12 days, Mann-Whitney U test, p = 0.02). Phenobarbitone treated infants tended to require second line treatment (47% v 35%, chi(2) test, p = 0.11) and SCBU admission (62% v 30%, chi(2) test, p = 0.04) more often.

Conclusions: Opiate replacement therapy appears to be superior for management of symptomatic NAS when maternal opiate use is prevalent. The shorter treatment duration and lower requirement for higher intensity nursing may have significant cost implications. Tailoring NAS treatment to local maternal drug use may result in similar benefits.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart summarising the study protocol for start, discontinuation, and dosage adjustment of treatments. NAS, Neonatal abstinence syndrome; TBG, true blood glucose; Rx, prescription; U+E, urea and electrolytes.

Similar articles

Cited by

References

    1. J Pediatr. 2001 Mar;138(3):344-8 - PubMed
    1. Eur J Pediatr. 1999 Jun;158(6):488-92 - PubMed
    1. Cochrane Database Syst Rev. 2002;(3):CD002053 - PubMed
    1. Cochrane Database Syst Rev. 2002;(3):CD002059 - PubMed
    1. Clin Pediatr (Phila). 1975 Jun;14(6):592-4 - PubMed

Publication types